Michael Rosenblatt, MD
Michael Rosenblatt, M.D., joined Flagship Pioneering in 2016, assuming the new position of chief medical officer, leading global clinical development and medical affairs. He plays a key role in Flagship’s internal venture creation team during the conception and launch of the next generation of pioneering biotechnology companies as well as serving as an ongoing strategic resource for all companies in the Flagship ecosystem by supporting their clinical development strategies. Additionally, he will serve on the board of directors of several portfolio companies; currently, he is on the board of directors of the Flagship companies Rubius Therapeutics (NASDAQ: RUBY)and Cygnal Therapeutics. In addition, he chairs or serves on the scientific or clinical advisory committees of several Flagship companies.
Michael joined Flagship from Merck, where he was executive vice president and chief medical officer from 2009 to 2016. During his career, he has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; president, Harvard faculty dean, and senior vice president for academic programs of Beth Israel Deaconess Medical Center; and director of the Harvard-MIT Division of Health Sciences and Technology. Michael is the holder of 19 patents and is author or co-author of over 180 peer-reviewed papers and commentaries.
After receiving his undergraduate degree summa cum laude from Columbia University, Michael earned his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital. In 1981 he was named chief of the Endocrine Unit at Massachusetts General Hospital. Michael was named senior vice president for research at Merck, Sharpe & Dohme Research Laboratories in 1984, and spent nearly a decade at Merck, co-leading the worldwide development of alendronate (FOSAMAX), Merck’s bisphosphonate for osteoporosis and bone disorders. In leading most of Merck’s international research efforts, he established two major basic research institutes. He also headed Merck Research’s worldwide University and Industry Relations Department.